147) dies to understand the plight of cervical cancer survivors regarding sexual dysfunct |
148) tive, and mixed methods studies of breast cancer survivors that examined FCR, HA, wo |
149) English from 2010-2020 that included: (1) cancer survivors who were AYAs (age 15-39 |
150) oss was particularly important for breast cancer survivors with clinically abnormal |
151) models of care utilized by adult Canadian cancer survivors. |
152) and young adult (AYA) (ages 15-39 years) cancer survivors. |
153) for racial/ethnic minorities of childhood cancer survivors. |
154) d a formal prehabilitation program before cancer treatment ("prehabilitation" listed |
155) health and psychosexual adjustment after cancer treatment are needed. |
156) Immunotherapy is the most promising new cancer treatment for various pediatric tum |
157) rch evidence about the impact of prostate cancer treatment on men's work lives. |
158) 0 that reported on the impact of prostate cancer treatment on men's work. |
159) s to improve functional capacity prior to cancer treatment to achieve better psychos |
160) herapy is rapidly emerging as a promising cancer treatment. |
161) g men's work-related plans after prostate cancer treatment. |
162) more gradual than expected after prostate cancer treatment. |
163) glutamine uptake an attractive target for cancer treatment. |
164) esuming work in the aftermath of prostate cancer treatment. |
165) ions limit the utility of BCG for bladder cancer treatment. |
166) Cancer pain is one of the most common symp |
167) ay yield effective strategies to overcome cancer pain barriers to improve the qualit |
168) r philosophical assumptions used to guide cancer pain management research is a cruci |
169) n management, factors such as barriers to cancer pain management still exist. |
170) suggested to address the main barriers of cancer pain management, focusing on the di |
171) in identifying and addressing barriers to cancer pain management. |
172) SCC, and that cathepsin S contributes to cancer pain through PAR2 on neurons. |
173) a role for cathepsin S in PAR2-dependent cancer pain. |
174) related pain, and as adjuvant therapy in cancer pain. |
175) s patients using cannabis for chronic non-cancer pain or spasticity. |
176) of 30-200 nm, providing highly effective cancer therapy due to the Enhanced Permeat |
177) nt pH-responsive drug release behavior in cancer therapy without using any targeting |
178) cogenic biomarker and target for targeted cancer therapy. |
179) should be an attractive strategy for lung cancer therapy. |
|